We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2015 by Eisai Inc..
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: September 11, 2006
Last Update Posted: July 1, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Eisai Inc.
September 8, 2006
September 11, 2006
July 1, 2015
June 2003
August 2007   (Final data collection date for primary outcome measure)
  • Confirmed response rate: Hepatocellular Cancer (HCC) Cohort: Response Evaluation Criteria in Solid Tumors (RECIST) criteria. [ Time Frame: Every 8 weeks until progression. ]
  • Hormone Refractory Prostate Cancer (HRPC) Cohort: Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and RECIST criteria. [ Time Frame: Every 8 weeks until progression. ]
  • Confirmed response rate
  • Hepatocellular (HCC) cohort - RECIST
Complete list of historical versions of study NCT00374660 on ClinicalTrials.gov Archive Site
  • Efficacy: HRPC Cohort: confirmed response rate according to RECIST; progression-free survival (PFS) for progression according to RECIST; new bone lesions or skeletal events; PFS according to PSA progression; overall survival. [ Time Frame: Every 8 weeks until progression. ]
  • Efficacy: HCC cohort - PFS (RECIST); overall survival [ Time Frame: Every 8 weeks until progression. ]
  • Efficacy
  • HCC cohort - PFS (RECIST), overall survival
Not Provided
Not Provided
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
Phase I-II Clinical and Pharmacokinetic Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
Not Provided
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Liver Cancer
Drug: Irofulven + oxaliplatin

Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. Starting dose 40 mg/m^2, dose escalation 50, 60, 70, and 80 mg/m^2 every 28 days if no dose-limiting toxicity.

Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered in a 30-minute infusion on Days 1 and 15 of a 28-day cycle. Starting dose 0.30 mg/kg, dose escalation to 0.40 mg/kg every 28 days if no dose-limiting toxicity.

Experimental: 1
Intervention: Drug: Irofulven + oxaliplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
Not Provided
August 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Signed informed consent obtained prior to initiation of any study-specific procedures and treatment.
  2. Malignant solid tumor confirmed by a biopsy sample.
  3. Pancreatic, endometrial, gastric, and hepatocellular cancer patients that have exhausted standard treatment options.
  4. Measurable disease according to RECIST.
  5. 18 years of age or older.
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-1.
  7. Life expectancy greater than 3 months.
  8. Previous anticancer treatment must be discontinued at least 4 weeks prior to first dose of study treatment (6 weeks for mitomycin C, 8 weeks for bicalutamide).
  9. Patients of reproductive age must be using effective contraceptive methods.
  10. Negative pregnancy test for patients of reproductive potential.

Exclusion Criteria:

  1. Prior therapy with irofulven or oxaliplatin.
  2. Patients who have had radiation therapy to more than 30% of the bone marrow prior to entry into the study.
  3. Prior chemotherapy with nitrosoureas or high dose carboplatin (AUC > 6), prior mitomycin C cumulative dose greater than or equal to 25 mg/m², prior bone marrow transplant or intensive chemotherapy with stem cell support.
  4. Presence of any serious concomitant systemic disorders incompatible with the study (e.g., uncontrolled congestive heart failure, active infection).
  5. Any previous history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry, unless the active malignancy can be unmistakably identified by evidence such as recent biopsies or tumor specific markers.
  6. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry.
  7. Pregnant or lactating patients or any patient with childbearing potential not using adequate contraception.
  8. Patients with retinopathy or significant visual impairment not correctable by refractory lens will be enrolled on a case by case basis according to the expected benefit ratio, taking into account the malignant disease and the existence of an objective decreased visual acuity and its degree.

Please note: There are additional criteria that must be met in order to be eligible for this study.

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Eisai Inc.
Eisai Inc.
Not Provided
Not Provided
Eisai Inc.
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP